RxDoctor Payments Data

Mark Cassol, MD

Ophthalmology · Louisville, KYNPI 1023128063

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,989 of the $4,921 with a category attached, or 81.1%. 14 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 40.3% of the total. Reporting peaked in 2019 at $1,767 and has fallen 71.5% since, to $503 in 2025.

$4,921in general payments, 2019–2025

Across 97 payments — averaging $50.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Alcon$1K
  • Ivantis, Inc$325
  • Merz North America, Inc.$299
  • Ocular Therapeutix, Inc.$187
  • NEW World Medical,inc.$168
  • plus $496 from 8 others

What the payments were for

  • Consulting fees$93219%
  • Food & beverage$3,98981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,921 in reported general payments places this provider in the 80th percentile of 216 ophthalmology providers in Kentucky.

See all ophthalmology providers in Kentucky

Medicare billing

Part B allowed, 2024
$189,147
Medicare patients
389
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine14$10,084
Prednisolone Acetate31$1,016
Latanoprost70$524
Acyclovir15$140
Brimonidine Tartrate23$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$17$10,08414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 216 ophthalmology providers in Kentucky.

Other ophthalmology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →